These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27736960)

  • 41. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multi-objective evolutionary algorithms for fuzzy classification in survival prediction.
    Jiménez F; Sánchez G; Juárez JM
    Artif Intell Med; 2014 Mar; 60(3):197-219. PubMed ID: 24525210
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The protective effect of vitamin E on locus coeruleus in early model of Parkinson's disease in rat: immunoreactivity evidence.
    Pasbakhsh P; Omidi N; Mehrannia K; Sobhani AG; Ragerdi Kashani I; Abbasi M; Kord Valeshabad A
    Iran Biomed J; 2008 Oct; 12(4):217-22. PubMed ID: 19079535
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
    Smith KM; Eyal E; Weintraub D;
    JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The dopamine mesocorticolimbic pathway is affected by deficiency in n-3 polyunsaturated fatty acids.
    Zimmer L; Vancassel S; Cantagrel S; Breton P; Delamanche S; Guilloteau D; Durand G; Chalon S
    Am J Clin Nutr; 2002 Apr; 75(4):662-7. PubMed ID: 11916751
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Heterogeneous composition of dopamine neurons of the rat A10 region: molecular evidence for diverse signaling properties.
    Li X; Qi J; Yamaguchi T; Wang HL; Morales M
    Brain Struct Funct; 2013 Sep; 218(5):1159-76. PubMed ID: 22926514
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 48. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
    Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
    Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DJ-1 protects against dopamine toxicity: implications for Parkinson's disease and aging.
    Lev N; Barhum Y; Pilosof NS; Ickowicz D; Cohen HY; Melamed E; Offen D
    J Gerontol A Biol Sci Med Sci; 2013 Mar; 68(3):215-25. PubMed ID: 22887838
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An Indian Family with Tyrosine Hydroxylase Deficiency.
    Goswami JN; Sankhyan N; Singhi PD
    Indian Pediatr; 2017 Jun; 54(6):499-501. PubMed ID: 28667724
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Computer-Aided Design for Identifying Anticancer Targets in Genome-Scale Metabolic Models of Colon Cancer.
    Cheng CT; Wang TY; Chen PR; Wu WH; Lai JM; Chang PM; Hong YR; Huang CF; Wang FS
    Biology (Basel); 2021 Oct; 10(11):. PubMed ID: 34827109
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fuzzy optimization for identifying anti-cancer targets with few side effects in constraint-based models of head and neck cancer.
    Wang FS; Chen PR; Chen TY; Zhang HX
    R Soc Open Sci; 2022 Oct; 9(10):220633. PubMed ID: 36303939
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Screening for Combination Cancer Therapies With Dynamic Fuzzy Modeling and Multi-Objective Optimization.
    Spolaor S; Scheve M; Firat M; Cazzaniga P; Besozzi D; Nobile MS
    Front Genet; 2021; 12():617935. PubMed ID: 33868363
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of the key target profiles underlying the drugs of narrow therapeutic index for treating cancer and cardiovascular disease.
    Yin J; Li X; Li F; Lu Y; Zeng S; Zhu F
    Comput Struct Biotechnol J; 2021; 19():2318-2328. PubMed ID: 33995923
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic change processes link and clarify targets and outcomes.
    Hofmann SG; Hayes SC
    World Psychiatry; 2019 Oct; 18(3):287-288. PubMed ID: 31496078
    [No Abstract]   [Full Text] [Related]  

  • 56. Fuzzy Decision Making Approach to Identify Optimum Enzyme Targets and Drug Dosage for Remedying Presynaptic Dopamine Deficiency.
    Hsu KC; Wang FS
    PLoS One; 2016; 11(10):e0164589. PubMed ID: 27736960
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fuzzy optimization for detecting enzyme targets of human uric acid metabolism.
    Hsu KC; Wang FS
    Bioinformatics; 2013 Dec; 29(24):3191-8. PubMed ID: 24078686
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Model-based optimization approaches for precision medicine: A case study in presynaptic dopamine overactivity.
    Hsu KC; Wang FS
    PLoS One; 2017; 12(6):e0179575. PubMed ID: 28614410
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease.
    Miller GW; Erickson JD; Perez JT; Penland SN; Mash DC; Rye DB; Levey AI
    Exp Neurol; 1999 Mar; 156(1):138-48. PubMed ID: 10192785
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.